Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Jérôme Galon,Jérôme Galon,Jérôme Galon,Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Helen K. Angell,Helen K. Angell,Anne Berger,Christine Lagorce,Alessandro Lugli,Inti Zlobec,Arndt Hartmann,Carlo Bifulco,Iris D. Nagtegaal,Richard Palmqvist,Giuseppe Masucci,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Michele Maio,Luigi Laghi,Fabio Grizzi,Martin Asslaber,Corrado D'Arrigo,Fernando Vidal-Vanaclocha,Eva Zavadova,Lotfi Chouchane,Pamela S. Ohashi,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Michael H.A. Roehrl,Linh V. Nguyen,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Yili Wang,Scott Kopetz,Frank A. Sinicrope,Viorel Scripcariu,Paolo A. Ascierto,Francesco M. Marincola,Bernard A. Fox,Bernard A. Fox,Franck Pagès +56 more
Reads0
Chats0
TLDR
In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC or UICCTNM classification.Abstract:
The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).read more
Citations
More filters
Journal ArticleDOI
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon,Daniela Bruni +1 more
TL;DR: A panel of therapeutic strategies to use, combine and develop to treat hot, altered and cold tumours is provided and the impact of combination therapy on the immune response to convert an immune cold into a hot tumour will be discussed.
Journal ArticleDOI
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pagès,Bernhard Mlecnik,Florence Marliot,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Fang Shu Ou,Carlo Bifulco,Alessandro Lugli,Inti Zlobec,Tilman T. Rau,Martin D. Berger,Iris D. Nagtegaal,Elisa Vink-Börger,Arndt Hartmann,Carol Geppert,Julie Kolwelter,Susanne Merkel,Robert Grützmann,Marc Van den Eynde,Anne Jouret-Mourin,Alex Kartheuser,Daniel Léonard,Christophe Remue,Julia Y. Wang,Julia Y. Wang,Prashant Bavi,Michael H.A. Roehrl,Michael H.A. Roehrl,Michael H.A. Roehrl,Pamela S. Ohashi,Linh T. Nguyen,Seong Jun Han,Heather L. MacGregor,Sara Hafezi-Bakhtiari,Bradly G. Wouters,Giuseppe Masucci,Emilia Andersson,Eva Zavadova,Michal Vocka,Jan Spacek,Lubos Petruzelka,Bohuslav Konopasek,Pavel Dundr,Helena Skalova,Kristyna Nemejcova,Gerardo Botti,Fabiana Tatangelo,Paolo Delrio,Gennaro Ciliberto,Michele Maio,Luigi Laghi,Fabio Grizzi,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Bénédicte Buttard,Bénédicte Buttard,Bénédicte Buttard,Mihaela Angelova,Mihaela Angelova,Mihaela Angelova,Angela Vasaturo,Angela Vasaturo,Angela Vasaturo,Pauline Maby,Pauline Maby,Pauline Maby,Sarah E. Church,Helen K. Angell,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Daniela Bruni,Daniela Bruni,Daniela Bruni,Carine El Sissy,Nacilla Haicheur,Amos Kirilovsky,Anne Berger,Christine Lagorce,Jeffrey P. Meyers,Christopher Paustian,Zipei Feng,Carmen Ballesteros-Merino,Jeroen R. Dijkstra,Carlijn van de Water,Shannon van Vliet,Nikki Knijn,Ana Maria Mușină,Dragos Viorel Scripcariu,Boryana Popivanova,Mingli Xu,Tomonobu Fujita,Shoichi Hazama,Nobuaki Suzuki,Hiroaki Nagano,Kiyotaka Okuno,Toshihiko Torigoe,Noriyuki Sato,Tomohisa Furuhata,Ichiro Takemasa,Kyogo Itoh,P. Patel,Hemangini H. Vora,Birva Shah,Jayendrakumar B. Patel,Kruti N. Rajvik,Shashank J. Pandya,Shilin N. Shukla,Yili Wang,Guanjun Zhang,Yutaka Kawakami,Francesco M. Marincola,Paolo A. Ascierto,Daniel J. Sargent,Bernard A. Fox,Bernard A. Fox,Jérôme Galon,Jérôme Galon,Jérôme Galon +120 more
TL;DR: The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.
Journal ArticleDOI
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey,Ling Tong,Yulin Li,Rachel K. Do,Susanne Walz,Kelly N. Fitzgerald,Arvin M. Gouw,Virginie Baylot,Ines Gütgemann,Ines Gütgemann,Martin Eilers,Dean W. Felsher +11 more
TL;DR: MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death–ligand 1).
Journal ArticleDOI
Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer
David D.L. Bowtell,David D.L. Bowtell,Steffen Böhm,Ahmed Ashour Ahmed,Paul Joseph Aspuria,Robert C. Bast,Valerie Beral,Jonathan S. Berek,Michael J. Birrer,Sarah P. Blagden,Michael A. Bookman,James D. Brenton,Katherine B. Chiappinelli,Filipe C. Martins,George Coukos,Ronny Drapkin,Richard J. Edmondson,Christina Fotopoulou,Hani Gabra,Jérôme Galon,Charlie Gourley,Valerie Heong,David G. Huntsman,Marcin P. Iwanicki,Beth Y. Karlan,Allyson Kaye,Ernst Lengyel,Douglas A. Levine,Karen H. Lu,Iain A. McNeish,Usha Menon,Steven A. Narod,Brad H. Nelson,Kenneth P. Nephew,Paul D.P. Pharoah,Daniel J. Powell,Pilar Ramos,Iris L. Romero,Clare L. Scott,Anil K. Sood,Euan A. Stronach,Frances R. Balkwill +41 more
TL;DR: This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015 and aims to reduce incidence and improve outcomes for women with this disease.
Journal ArticleDOI
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Pauline Maby,Mihaela Angelova,David Tougeron,Sarah E. Church,Sarah E. Church,Sarah E. Church,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Maria Fischer,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Maristella Sasso,Maristella Sasso,Maristella Sasso,Amélie M. Bilocq,Amélie M. Bilocq,Amélie M. Bilocq,Amos Kirilovsky,Amos Kirilovsky,Amos Kirilovsky,Anna C. Obenauf,Mohamad Hamieh,Anne Berger,Patrick Bruneval,Jean-Jacques Tuech,Jean-Christophe Sabourin,Florence Le Pessot,Jacques Mauillon,Arash Rafii,Pierre Laurent-Puig,Pierre Laurent-Puig,Michael R. Speicher,Zlatko Trajanoski,Pierre Michel,Richard Sesboüé,Thierry Frebourg,Thierry Frebourg,Franck Pagès,Viia Valge-Archer,Viia Valge-Archer,Jean-Baptiste Latouche,Jérôme Galon,Jérôme Galon,Jérôme Galon +52 more
TL;DR: Assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging that could be an important guide for immunotherapy strategies.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon,Anne Costes,Fátima Sánchez-Cabo,Amos Kirilovsky,Bernhard Mlecnik,Christine Lagorce-Pagès,Marie Tosolini,Matthieu Camus,Anne Berger,Philippe Wind,Franck Zinzindohoué,Patrick Bruneval,Paul-Henri Cugnenc,Zlatko Trajanoski,Wolf H. Fridman,Franck Pagès +15 more
TL;DR: In situ analysis of tumor-infiltrating immune cells may be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Related Papers (5)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more